Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Therapy. (September 2014)

• Record Type: Journal Article
• Authors: Lam, Justina Yick Ching; Ng, Matthew Chau Hsien
• Is Part Of: Proceedings of Singapore healthcare. Volume 23:Number 3(2014)
• Page Start: 241
• Page End: 245
• Publication Date: 2014-09
• Subjects: Leucoencephalopathy -- Anti-angiogenic -- PRES -- VEGF -- anti-cancer; Medical care -- Singapore -- Periodicals; Medical care; Singapore; Periodicals; 362.1095957
• DOI: 10.1177/201010581402300309
• Languages: English
• ISSNs: 2010-1058

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity first described in 1996 by Hinchey et al, most commonly associated with hypertensive encephalopathy, eclampsia in pregnant women, immunosuppressants and cytotoxic agents. In recent years, anti-angiogenic agents as a novel class of anti-cancer therapies have become a standard of care for certain tumours. Correspondingly, there have been an emerging number of case reports documenting PRES associated with these anti-angiogenic therapies. As the manifestations of PRES are often non-specific, but could rarely lead to permanent neurological disability or even death, it is crucial that physicians are aware of PRES in relation to anti-angiogenic therapy to promptly institute appropriate management to achieve the best outcomes for patients.